The CBCE - Online Education Activity Detail

	Log In

Emerging Strategies for the Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndromes: Progress and Challenges

An Archived Webcast

Program Chair: Jean-Pierre Issa, MD
Release Date: January 15, 2010
Expiration Date: January 14, 2011


	THIS ACTIVITY IS AVAILABLE IN THE FOLLOWING METHODS: Webcast

Estimated Time to Complete Each Session: 30 Minutes

Statement of Need
Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal myeloid hemopathies resulting in 1 or more peripheral blood cytopenias. Depending on their MDS subtype, these patients have a 5%-55% risk of transformation to acute myeloid leukemia (AML), a malignancy with a much poorer prognosis. Even in the absence of progression to AML, fatal complications resulting from peripheral blood cytopenias can occur. Although several new agents have been approved for AML and MDS in recent years, a compelling need remains for the development of improved therapies, as median survival for even low-risk MDS is less than 6 years and for AML is, even worse, less than 1 year. A number of novel agents are currently under investigation as potential therapies for AML and/or MDS, including demethylating agents, histone deacetylase inhibitors, immunomodulatory agents, immunosuppressive therapies, kinase inhibitors, novel chemotherapies, proteasome inhibitors, and apoptotic agents. Allogeneic stem cell transplantation (SCT) has curative potential for both AML and MDS; however, its associated treatment-related morbidity and mortality limit the number of patients that can receive it.

Participants of this webcast will learn about aberrant signaling pathways and potential targets of these diseases, as well as clinical data on emerging therapies. They will also hear about the difficulties and strategies involved with allogeneic transplantation and the treatment of a challenging patient population, the elderly.

Target Audience
This activity is intended for hematologists, physician assistants, and other healthcare professionals interested in the treatment of patients with hematologic malignancies.

Method of Participation for Webcast

This activity requires that your computer be configured to access the Internet. A high-speed Internet connection may be required to view large files. The webcast will be available on www.thecbce.com. The webcast will also be a featured program on the CBCE CME app, which may be downloaded from the Apple^® App Store for use on the iPhone^® or iPod touch^®.

Method of Participation for iPhone^® or iPod touch^®

This activity can be accessed using an iPhone^® or iPod touch^® and will be a featured program on the CBCE CME app, which may be downloaded from the Apple^® App Store.

Session 1: Molecular Characterization of AML and MDS: Diagnostic and Prognostic Biomarkers

Stephen D. Nimer, MD

Educational Objective
Upon completion of this activity, participants will be able to

Assess the emerging clinical role of biomarkers in the management of AML and MDS.

Session 2: Emerging Novel Agents for the Treatment of MDS

Guillermo Garcia-Manero, MD

Educational Objective
Upon completion of this activity, participants will be able to

Summarize the novel agents in clinical trials for the treatment of MDS.

Session 3: Treating Elderly Patients With AML

Jeffrey E. Lancet, MD

Educational Objective
Upon completion of this activity, participants will be able to

Discuss the specific issues involved with the treatment of elderly patients with AML.

Session 4: Integrating Novel Agents Into Current Therapies for AML

Jean-Pierre Issa, MD

Educational Objective
Upon completion of this activity, participants will be able to

Outline the novel agents under investigation for the treatment of AML.

Session 5: Challenges in Allogeneic Stem Cell Transplantation: Strategies for Individualizing Therapy in AML and MDS

Elihu Estey, MD

Educational Objective
Upon completion of this activity, participants will be able to

Describe the strategies involved in the optimal use of allogeneic SCT for the treatment of AML and MDS.

Accreditation

Physicians: The CBCE™ (The Center for Biomedical Continuing Education) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The CBCE designates each session for a maximum of .50 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in this activity.

Physician Assistants: AAPA accepts certificates of participation for educational activities certified for Category 1 credit from AOACCME, Prescribed credit from AAFP, and AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of .50 hour of Category 1 credit for completing each session.

Nurses: The CBCE™ (The Center for Biomedical Continuing Education) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

The CBCE designates each session for a maximum of .50 contact hour.

Accreditation by the American Nurses Credentialing Center’s Commission on Accreditation refers to recognition of educational activities and does not imply approval or endorsement of any product.

Pharmacists: The CBCE™ (The Center for Biomedical Continuing Education) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.
CPE Credit: .50 contact hour or 0.050 CEU
Universal Activity Number: 0195-0000-10-001-H01-P

Webcast Credit Instructions

Successful completion of this activity includes the following:

Score 70% or above on the posttest.
Complete the Evaluation and Request for Credit Form.
Fax the completed posttest and form to the CBCE, (214) 260-0509

Participants will receive their certificate 4-6 weeks after the CBCE receives their posttest and form.

CBCE CME App Credit Instructions

Successful completion of this activity includes the following:

Complete the online posttest and score 70% or above.
Complete the online Evaluation and Request for Credit Form.

Participants will receive their certificates via e-mail 4-6 weeks after submission of the online Evaluation and Request for Credit Form.

Participants of the live activity are not eligible to receive credit for this activity.

Acknowledgement of Commercial Support
The CBCE gratefully acknowledges the educational grant provided by Eisai Inc.

Educational Inquiries
For further information, please contact the CBCE, 1707 Market Place Blvd., Suite 370, Irving, TX 75063; Phone: (214) 260-9024; Fax: (214) 260-0509; E-mail: info@thecbce.com.

Disclaimer
The content and views presented in this educational activity are those of the faculty and do not necessarily reflect the opinions or recommendations of the CBCE or Eisai Inc. This material has been prepared based on a review of multiple sources of information but is not comprehensive. Participants are advised to critically appraise the information presented, and they are encouraged to consult the available literature on any product or device mentioned in this program.

Disclosure of Unlabeled Uses
This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the US Food and Drug Administration. For additional information about approved uses, including approved indications, contraindications, and warnings, please refer to the prescribing information for each product or consult the latest edition of the Physicians’ Desk Reference.

Disclosure of Financial Relationships With Any Commercial Interest

Faculty who refuse to disclose relevant financial relationships will be disqualified from being a planning committee member, a teacher, or an author, and cannot have control of or responsibility for the development, management, presentation, or evaluation of the educational activity. For an individual with no relevant financial relationship, participants must be informed that no relevant financial relationship exists.

Disclosure of Potential Conflicts of Interest

The CBCE assesses conflicts of interest with its faculty, planners, and managers of CBCE activities. Identified conflicts of interest are thoroughly evaluated for fair balance, scientific objectivity relative to studies utilized in this activity, and patient-care recommendations. The CBCE is committed to providing participants with high-quality, unbiased, and state-of-the-art education.

The following faculty reported real or apparent conflicts of interest, and these conflicts have been resolved through a peer-review process:

Jean-Pierre Issa, MD
Consultant
Eisai Inc.
Grant/Research Support
Eisai Inc.
Celgene Corporation
Merck & Co.
Honoraria
Eisai Inc.

Jeffrey E. Lancet, MD
Consultant
Eisai Inc.
Genzyme Corporation
Grant/Research Support
Celgene Corporation

Stephen D. Nimer, MD
Consultant
Amgen Inc.
Celgene Corporation
Eisai Inc.
Genzyme Corporation

The following faculty declared they have no financial relationships that require disclosure:

Elihu Estey, MD
Guillermo Garcia-Manero, MD

Institutional Disclosure
The CBCE receives educational grants from the pharmaceutical industry and other commercial sources. Companies providing grants to the CBCE include the commercial supporter of this activity as well as the manufacturers of certain drugs and/or devices discussed in this activity.

Staff Disclosure
The CBCE staff have declared they have no financial relationships that require disclosure.